Dall’Era, M., Kalunian, K., Solomons, N., Truman, M., Hodge, L. S., Yap, E., & Askanase, A. D. (2024). Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Science & Medicine, 11(2), e001319. https://doi.org/10.1136/lupus-2024-001319

Inzerillo, S., Schwartz, N., Khalili, L., April Fu, W. Y., Tang, W., Pardilla, L. G.-, Gartshteyn, Y., Schmidt, N., Izmirly, P., & Askanase, A. (2024). 104 Demographic and clinical factors that contribute to clinical study enrollment in systemic lupus erythematosus. Achieving Equity in Lupus Care & Outcomes. https://doi.org/10.1136/lupus-2023-lupus21century.4

Tang, W., Marone, A., Khalili, L., Wang, X., Murray, S., Inzerillo, S., Bardien, M., Gaikwad, V., Kim, S., Geraldino-Pardilla, L., Hielscher, A., & Askanase, A. (2024). 616 Comparison of optical and ultrasound imaging in lupus arthritis. Epidemiology & Outcomes. https://doi.org/10.1136/lupus-2023-lupus21century.45

Askanase, A. D., Furie, R. A., Dall’Era, M., Bomback, A. S., Schwarting, A., Zhao, M.-H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R. A., van Vollenhoven, R., & Urowitz, M. B. (2024). Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Science & Medicine, 11(1), e001124. https://doi.org/10.1136/lupus-2023-001124

Krustev, E., Hanly, J. G., Chin, R., Buhler, K. A., Urowitz, M. B., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sánchez-Guerrero, J., Bernatsky, S., Wallace, D. J., Isenberg, D., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M. A., Ginzler, E. M., … Choi, M. Y. (2024). Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus. Lupus Science & Medicine, 11(1), e001139. https://doi.org/10.1136/lupus-2023-001139

Dall’Era, M., Kalunian, K., Askanase, A., Solomons, N., Truman, M., Hodge, L., & Yap, E. (2024). P87 Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV plus AURORA 1 studies and ALMS. Poster Presentations, A104.2-A105. https://doi.org/10.1136/lupus-2024-el.141

Garces, S., Karis, E., Merrill, J. T., Askanase, A. D., Kalunian, K., Mo, M., & Milmont, C. E. (2023). Improving resource utilisation in SLE drug development through innovative trial design. Lupus Science & Medicine, 10(2), e000890. https://doi.org/10.1136/lupus-2022-000890

Connelly, K., Eades, L., Koelmeyer, R., Ayton, D., Golder, V., Kandane-Rathnayake, R., Gregory-Wong, K., Brunner, H., Burke, L., Arnaud, L., Askanase, A., Aranow, C., Vital, E., Pons-Estel, G., Dantata, K., Sun, Y., Tanaka, Y., Lee, S., Lahoud, Y., … Morand, E. (2023). LO-033 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials – first outcomes of an international consensus process. Oral Presentation. https://doi.org/10.1136/lupus-2023-kcr.34

Lee, J.-Y. (Esther), Mendel, A., Askanase, A., Bae, S.-C., Buyon, J., Clarke, A. E., Costedoat-Chalumeau, N., Fortin, P. R., Gladman, D., Ramsey-Goldman, R., Hanly, J. G., Inanç, M., Isenberg, D., Mak, A., Mosca, M., Petri, M., Rahman, A., Sanchez-Guerrero, J., Urowitz, M., … Vinet, É. (2023). LSO-083 ‘Systemic lupus erythematosus women with lupus nephritis in pregnancy therapeutic challenge (SWITCH)’: the systemic lupus international collaborating clinics experience. Short Oral Presentation. https://doi.org/10.1136/lupus-2023-kcr.124

Askanase, A. D., Aranow, C., Kim, M. Y., Kamen, D. L., Arriens, C., Khalili, L., Tang, W., Barasch, J., Dall’Era, M., & Mackay, M. (2023). Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus Science & Medicine, 10(2), e000952. https://doi.org/10.1136/lupus-2023-000952

Askanase, A. D., Tang, W., Zuraw, Q., Gordon, R., Brotherton, B., & Merrill, J. T. (2023). Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE. Lupus Science & Medicine, 10(1), e000875. https://doi.org/10.1136/lupus-2022-000875

Buie, J., Bloch, L., Morand, E. F., van Vollenhoven, R. F., Werth, V. P., Touma, Z., Lipsky, P., Kalunian, K., Askanase, A. D., Ines, L., Reed, C., Son, M., Franson, T., Costenbader, K., & Schanberg, L. E. (2023). Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective. Lupus Science & Medicine, 10(1), e000901. https://doi.org/10.1136/lupus-2023-000901

Becker, Y. L., Boilard, É., Rollet-Labelle, E., Lood, C., Julien, A.-S., Leclerc, J., Lévesque, T., Urowitz, M., Hanly, J., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Clarke, A. E., Bernatsky, S., Wallace, D., Isenberg, D., Rahman, A., Merrill, J., … Fortin, P. R. (2022). 103 Exploratory segregation of patients upon their levels of anti- mitochondrial antibodies (AMAs) reveals associations between AMAs and disease manifestations. Lupus 21st Century 2022. https://doi.org/10.1136/lupus-2022-lupus21century.3

Inzerillo, S., Weiner, J., Tang, W., Khalili, L., Barasch, J., Izmirly, P., Kaplan, S., Geraldino-Pardilla, L., Gartshteyn, Y., Schmidt, N., & Askanase, A. (2022). 609 Demographic and clinical factors that contribute to clinical study enrollment. Clinical Research in SLE. https://doi.org/10.1136/lupus-2022-lupus21century.30

Askanase, A. D., Aranow, C., Kim, M., Kamen, D., Arriens, C., Tang, W., Khalili, L., Barasch, J., Dall’Era, M., & Mackay, M. (2022). 617 Evaluation of SLE outcome measures in telemedicine: interim analysis results. Clinical Research in SLE. https://doi.org/10.1136/lupus-2022-lupus21century.38

Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M., Clarke, A. E., Ruiz-Irastorza, G., Gordon, C., Ramsey-Goldman, R., Petri, M. A., Ginzler, E. M., Wallace, D. J., Bae, S.-C., Romero-Diaz, J., Dooley, M.-A., Peschken, C., Isenberg, D., Rahman, A., Manzi, S., Jacobsen, S., Lim, S. S., … Bernatsky, S. (2022). Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine. Lupus Science & Medicine, 9(1), e000789. https://doi.org/10.1136/lupus-2022-000789

Cardwell, F. S., Elliott, S. J., Chin, R., St Pierre, Y., Choi, M. Y., Urowitz, M. B., Ruiz-Irastorza, G., Bernatsky, S., Wallace, D. J., Petri, M. A., Manzi, S., Bae, S.-C., Shin, J.-M., Mak, A., Cho, J., Peschken, C. A., Ramsey-Goldman, R., Fortin, P. R., Hanly, J. G., … Clarke, A. E. (2022). Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic. Lupus Science & Medicine, 9(1), e000755. https://doi.org/10.1136/lupus-2022-000755

van Vollenhoven, R., Askanase, A. D., Bomback, A. S., Bruce, I. N., Carroll, A., Dall’Era, M., Daniels, M., Levy, R. A., Schwarting, A., Quasny, H. A., Urowitz, M. B., Zhao, M.-H., & Furie, R. (2022). Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Science & Medicine, 9(1), e000634. https://doi.org/10.1136/lupus-2021-000634

Ugarte-Gil, M. F., Mak, A., Leong, J., Dharmadhikari, B., Kow, N. Y., Reátegui-Sokolova, C., Elera-Fitzcarrald, C., Aranow, C., Arnaud, L., Askanase, A. D., Bae, S.-C., Bernatsky, S., Bruce, I. N., Buyon, J., Costedoat-Chalumeau, N., Dooley, M. A., Fortin, P. R., Ginzler, E. M., Gladman, D. D., … Alarcon, G. S. (2021). Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science & Medicine, 8(1), e000590. https://doi.org/10.1136/lupus-2021-000590